Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Olorofim

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    F2G Secures $100M For Olorofim Development And Commercialization
    F2G Secures $100M For Olorofim Development And Commercialization

    12 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/12/2945064/0/en/F2G-Announces-100-Million-Financing-to-Advance-Late-Stage-Development-and-Commercialization-of-Novel-Antifungal-Drug-Candidate-Olorofim-in-the-US.html

    GLOBENEWSWIRE
    12 Sep 2024
    Share Share
    F2G Receives CRL from FDA for New Drug Application for Olorofim
    F2G Receives CRL from FDA for New Drug Application for Olorofim

    20 Jun 2023

    // FINANCE YAHOO

    https://finance.yahoo.com/news/f2g-receives-complete-response-letter-113000837.html

    FINANCE YAHOO
    20 Jun 2023
    Share Share
    F2G Receives CRL from FDA for NDA for Olorofim for The Treatment
    F2G Receives CRL from FDA for NDA for Olorofim for The Treatment

    19 Jun 2023

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/f2g-receives-crl-from-fda-for-nda-for-olorofim-for-the-treatment-14551.pdf

    PRESS RELEASE
    19 Jun 2023
    Share Share
    F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim
    F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim

    13 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/13/2534044/0/en/F2G-to-Present-Interim-Results-from-Phase-2B-Open-Label-Study-of-Olorofim-in-Invasive-Fungal-Infections-at-IDWeek-2022.html

    GLOBENEWSWIRE
    13 Oct 2022
    Share Share
    Novo Holdings, Shionogi offer treatment for invasive fungal infections
    Novo Holdings, Shionogi offer treatment for invasive fungal infections

    16 May 2022

    // BIOSPECTRUMASIA

    https://www.biospectrumasia.com/news/25/20293/novo-holdings-shionogi-offer-treatment-for-invasive-fungal-infections-in-europe-and-asia.html

    BIOSPECTRUMASIA
    16 May 2022
    Share Share
    F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis
    F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis

    09 Jun 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/f2gs-olorofim-receives-both-fda-orphan-drug-designation-for-coccidioidomycosis-valley-fever-and-fda-qidp-designation-for-multiple-fungal-infections-301073101.html

    PRNEWSWIRE
    09 Jun 2020
    Share Share